Is aspirin safe in heart failure? More data SIR,-We recently reviewed the evidence for an interaction between aspirin and ACE inhibitors on mortality in heart failure.' At that time the data from SOLVD (studies of left ventricular dysfunction), the most alarming evidence of an interaction, had been presented but not published. The 
SIR,-We recently reviewed the evidence for an interaction between aspirin and ACE inhibitors on mortality in heart failure.' At that time the data from SOLVD (studies of left ventricular dysfunction), the most alarming evidence of an interaction, had been presented but not published. The data have now been published in abstract form (table) .2 The authors suggest that the data support a beneficial effect of aspirin in heart failure, though the administration of aspirin was not randomised. The arguments suggesting the reverse were presented by us in our review. ' Careful scrutiny of the SOLVD data suggest that the lowest mortality in both the treatment and prevention arms of SOLVD was among patients taking placebo and aspirin (Bi and Dl in the table). Assertion that aspirin is beneficial, based on these data, would logically lead one to withdraw the ACE inhibitor, at least if it were being given to reduce mortality rather than to improve symptoms. This would be flying in the face of the data from properly constructed randomised controlled trials. If one accepts that enalapril is effective, based on a properly randomised comparison, then it is evident that the addition of aspirin is of little or no benefit in patients with heart failure (comparison of Cl and C2 in Lancet 1995; 346: 196-7. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation SIR,-Dubrey and colleagues reported on a series of patients with cardiac amyloidosis, atrial thrombi, and evidence of atrial electromechanical dissociation. They suggested that systemic anticoagulation may be indicated when atrial systolic function is impaired.' Plehn et al described a similar case presenting with systemic embolisation and again recommended anticoagulation for atrial failure in amyloidosis.5
It is perhaps worth noting that atrial dysfunction may be the first manifestation of previously unrecognised amyloid heart disease and that atrial systolic failure can precede clinically detectable ventricular involvement.
We have reported a case of apparent isolated atrial cardiomyopathy complicated by systemic embolisation.34 Diagnostic evaluation at presentation showed dilated, akinetic atria with normal ventricular function. Endomyocardial, rectal, and skeletal muscle biopsies performed at this time did not show any histological evidence of amyloidosis. The patient progressed over several years to ventricular dysfunction and died in congestive heart failure. Necropsy was not performed but ventricular biopsies had been obtained some months previously during an elective operation to replace the tricuspid valve. These showed systemic amyloidosis.
Cardiac amyloidosis should be considered in the differential diagnosis of patients presenting with atrial systolic failure: systemic anticoagulation seems to be indicated in these cases. 
